ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 813

Identifying and Assessing Subgroups in Systemic Sclerosis Patients Based on Comprehensive Autoantibody Profiling

Petra Budde1, Hans-Dieter Zucht1, Heike Göhler1, Klaus Marquart1, Peter Schulz-Knappe1, Matthias Schneider2 and Nicolas Hunzelmann3, 1Protagen AG, Dortmund, Germany, 2Rheumatology, Heinrich-Heine-University, Duesseldorf, Germany, 3Department of Dermatology, University of Cologne, Cologne, Germany

Meeting: 2016 ACR/ARHP Annual Meeting

Date of first publication: September 28, 2016

Keywords: autoantibodies, autoantigens, Biomarkers and systemic sclerosis, Disease Sub-phenotyping

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, November 13, 2016

Title: Systemic Sclerosis, Fibrosing Syndromes and Raynaud's – Pathogenesis, Animal Models and Genetics - Poster I

Session Type: ACR Poster Session A

Session Time: 9:00AM-11:00AM

Background/Purpose: Systemic sclerosis (SSc) is a remarkably heterogeneous autoimmune disease, for which effective disease-modifying therapies are still lacking. The most widely used classification divides SSc into two major subsets diffuse cutaneous (dcSSc) and limited (lcSSc) SSc by the extent and severity of skin fibrosis. However, not all patients fit into these subsets. This has created great interest to examine disease heterogeneity at the molecular level to uncover unrecognized SSc subtypes that may differ with regard to clinical manifestations, prognosis or therapy response. In large-scale “omics”-type autoantibody (AAB) profiling studies we have recently identified novel SSc-associated autoantigens. Here, we describe the development of a 20 marker multiplexed AAB assay and explored its utility for SSc patient subgroup analysis.

Methods: A Luminex bead-based AAB assay was designed by combining 8 connective tissue disease (anti-centromere, anti-Scl70, U1-snRNP, SSB, Ro52, Ro60, SmB, anti-ribosomal P) antigens with 12 novel antigens (including BICD2, JMJD3/KDM6B, and PPP1R2). Novel AAB targets were previously detected in SSc patients with a p-value <0.05 (Mann-Whitney-U-test) and frequency >15%. AAB reactivity was analysed in 100 SSc patients (dcSSc: n=32, lcSSc: n=50, SSc overlap: n=9, other: n=9). The mean modified Rodnan skin score (MRSS), mean disease duration (month), and mean age (years) of the SSc cohort was 10.51, 162.5 and 56.94, respectively. To analyze the individual-level patient similarity of AAB reactivity, the total number of AABs reactive in each patient was calculated and referenced to the number of all available antigens in percent. Hierarchical cluster analysis of marker co-prevalence and patient signature overlap was performed.

Results: Based on their AAB reactivity pattern, the SSc sample cohort can be decomposed into four main clusters. Cluster 1 includes 87% of all lcSSc patients characterized by an extended AAB repertoire (including BICD2, KDM6B and PPP1R2), MRSS below the average and longer disease duration. Cluster 2 includes 56% lcSSc and 26 % dcSSc patients characterized by MRSS above the average and anti-U1-snRNP antibodies. Cluster 3 includes SSc-overlap, lcSSc and dcSSc with higher MRSS compared to Cluster 1 and 2 and variable AAB profile. Cluster 4 includes mainly dcSSc patients with anti-Scl70 AAB and highest number of patients with MRSS above the average (83%).

Conclusion: The multiplexed analysis of AABs in SSc enables defining an AAB reactivity score and patient clusters. This might support to subclassify SSc beyond lcSSc and dSSc.


Disclosure: P. Budde, Protagen AG, 3; H. D. Zucht, Protagen AG, 3; H. Göhler, Protagen AG, 3; K. Marquart, Protagen AG, 3; P. Schulz-Knappe, Protagen AG, 3; M. Schneider, Protagen AG, 5; N. Hunzelmann, None.

To cite this abstract in AMA style:

Budde P, Zucht HD, Göhler H, Marquart K, Schulz-Knappe P, Schneider M, Hunzelmann N. Identifying and Assessing Subgroups in Systemic Sclerosis Patients Based on Comprehensive Autoantibody Profiling [abstract]. Arthritis Rheumatol. 2016; 68 (suppl 10). https://acrabstracts.org/abstract/identifying-and-assessing-subgroups-in-systemic-sclerosis-patients-based-on-comprehensive-autoantibody-profiling/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2016 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/identifying-and-assessing-subgroups-in-systemic-sclerosis-patients-based-on-comprehensive-autoantibody-profiling/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology